Cohance Lifesciences Limited — Updates, 25-04-2025: Press Release

Suven Pharmaceuticals Limited has received final regulatory approval for the amalgamation with Cohance Lifesciences Limited, with the merger set to take effect from the business opening hours of May 1, 2025. This significant milestone is expected to enhance Suven's capabilities as a leading contract development and manufacturing organization (CDMO), enabling the company to offer more advanced solutions, particularly in Antibody-Drug Conjugates (ADCs) and complex chemical platforms. The merged entity will operate under the name Cohance Lifesciences Limited, reinforcing their strategy to build a differentiated global CDMO.

Additionally, the Board has set the Record Date for eligible shareholders of Cohance Lifesciences Limited to receive equity shares of Suven Pharmaceuticals on May 8, 2025. This integration is aligned with Suven's ambition to achieve US$1 billion in revenue through both organic growth and strategic acquisitions, demonstrating a positive outlook for their growth trajectory. Operational integration is already underway, combining strengths in technology and execution across the pharmaceutical value chain.